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"I am just a child who has never grown up. I still keep asking
these ‘how’ and ‘why’ questions. Occasionally, I find an
answer."
Stephen Hawking

Abstract
Amyotrophic Lateral Sclerosis is a fatal neurodegenerative disease affecting upper and
lower motor neurons. Patients display progressive paralysis with death typically result-
ing from diaphragmatic failure. Considerable evidence points out for a significant, but
nevertheless complex genetic contribution for both ALS forms, familial and sporadic.
Hence, subsequent work has identified a broad set of mutated genes associated with ALS
symptoms, including Fused in Sarcoma (FUS).
Not surprisingly, current efforts to develop new treatments for ALS involve the identi-
fication of small molecules that counteract the cellular hallmarks of the pathology. Ample
evidence suggests that small bioactive molecules such as polyphenols have protective ef-
fects in neurodegenerative disorders. In fact, many studies have been supporting the
possibility of changing the progression of the neurodegeneration through diet.
Our study had a two-fold objective: to characterize the neuronal and kinematic decay
of a Drosophila model of ALS; to test the protective effect of a small molecule previously
identified for its capability to improve cellular growth of a yeast model overexpressing
FUS. Since Drosophila has a relatively complex nervous system and a stereotyped set
of motor outputs, it represents a step forward in the validation of this promising small
molecule.
Consistent with previous transgenic models, the Drosophila model of ALS overexpress-
ing human FUS alleles (wild type and R521C) exhibited locomotor deficits, impairment
of the climbing ability, reduced reproduction and shortened life span, with the degree
of severity of mutant FUS phenotypes more aggressive than the wild type form. Fur-
thermore, a detailed analysis of the locomotor pattern of the flies modelling ALS, using
the custom-made FlyWalker system, revealed that the motor phenotype of these flies is
evident after 14 days of FUS wild type expression. In addition, FUS wild type transgenic
flies exposed to 10 mM of the small molecule showed a significant increase in the survival
rate. Collectively, we conclude that the Drosophila model captures important aspects of
human FUS-based ALS, providing a useful tool to test the efficacy of bioactive molecules.
Keywords: Amyotrophic Lateral Sclerosis; Fused in Sarcoma; Neurodegeneration; Polyphe-
nols
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Resumo
A Esclerose Lateral Amiotrófica (ELA) é uma doença neurológica degenerativa fatal.
Nesta patologia, os neurónios motores que conduzem a informação do cérebro aos múscu-
los, passando pela medula espinhal, morrem prematuramente. Deste modo, os pacientes
sofrem paralisia gradual e morte precoce devido à perda de capacidades essenciais, como
andar, falar, engolir e até mesmo respirar. Com os avanços da genética molecular, alguns
genes responsáveis por ambas as formas clínicas da doença (esporádica e familiar) fo-
ram caracterizados, incluindo o SOD1 (Superoxide Dismutase 1), o TDP-43 (Transactive
Response DNA-binding protein-43) e o FUS (Fused in Sarcoma). Além disso, alguns me-
canismos celulares associados à neurodegeneração incluem a agregação de proteínas, o
stress do Retículo Endoplasmático, o stress oxidativo e a neuroinflamação.
Atualmente, os esforços para desenvolver novos tratamentos para a ELA involvem a
identificação de moléculas que contrariem as características celulares da patologia. Am-
plas evidências sugerem que moléculas bioativas, tais como os polifenóis, têm efeitos
protetores nas doenças neurodegenerativas. De fato, muitos estudos têm apoiado a possi-
bilidade de alterar a progressão da neurodegeneração através da dieta.
Portanto, o nosso estudo teve dois principais objetivos: por um lado, caracterizar o
decaimento neuronal e cinemático de um modelo de Drosophila de ELA e por outro, testar
o efeito protetor de uma pequena molécula bioactiva previamente identificada pela sua
capacidade de melhorar o crescimento celular de um modelo de levedura que expressa
FUS. Uma vez que a Drosophila possui um sistema nervoso relativamente complexo e um
conjunto estereótipado de neurónios motores, representa um excelente modelo animal
para a validação desta molécula promissora.
Consistente com os modelos transgénicos anteriores, o modelo de Drosophila de ELA
expressando alelos FUS humanos (tipo selvagem e R521C, uma mutação comum em
pacientes com ELA) exibiu neurodegeneração, dificuldades locomotoras, capacidade de
subida comprometida e reprodução e vida útil reduzida, sendo os fenótipos dos mutantes
mais agressivos do que os da forma selvagem. Além disso, uma análise detalhada do
padrão locomotor das moscas que modelam a ELA, usando o sistema FlyWalker, revelou
que o fenótipo motor dessas moscas é evidente após 14 dias de expressão do FUS (forma
selvagem). Adicionalmente, as moscas transgénicas do tipo FUS selvagem expostas a 10
xi
mM da molécula bioactiva mostraram um aumento significativo na taxa de sobrevivência.
Deste modo, concluímos que o modelo de Drosophila de ELA possui aspetos impor-
tantes da doença humana, sendo uma ferramenta importante para testar a eficácia de
moléculas bioactivas.
Palavras-chave: Esclerose Lateral Amiotrófica; FUS; Neurodegeneração; Polifenóis
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Introduction
1.1 Context and Motivation
Amyotrophic Lateral Sclerosis is an adult-onset neurodegenerative disorder characterized by
the loss of motor neurons in the brain or spinal cord leading to progressive paralysis and
consequently death from respiratory failure within 3-5 years after diagnosis on average [2, 66].
ALS, like most of the neurodegenerative disorders, starts focally and spreads progres-
sively: symptoms begin with weakness or muscle cramping and progress to paralysis of
nearly all skeletal muscles. Due to improved care, evidence has shown that survival is
increasing [24] but some mechanisms implicated in the death of the motor neurons are
still unclear and there is no effective therapy for preventing the neurodegeneration. Thus,
ALS disease has a fatal progressive course [66, 72, 76].
About 10% of cases of ALS are transmitted within families, frequently as dominant
traits. Nevertheless, Mendelian genes were also found mutated in individuals with no
family history, suggesting a complex genetic contribution to both ALS forms, sporadic
and familial. Thus, advances in genetic testing techniques led to the discovery of some
ALS causative genes, including Superoxide Dismutase 1 (SOD1), Transactive Response
DNA-binding protein-43 (TARDBP or TDP-43) and Fused in Sarcoma (FUS)[66].
Due to the large number of gene mutations associated with this disease, a plethora
of toxic mechanisms mediating the degeneration and death of motor neurons have been
proposed. Several hypothesis have emerged leading to the identification of genetic and
biochemical markers and providing therapeutic targets including protein aggregation,
ER stress and impairment of protein degradation, mitochondrial dysfunction and neu-
roinflammation, among others [2, 66].
In 1995, the Food and Drug Administration (FDA) approved the first drug for ALS
treatment known as riluzole, a glutamate antagonist. In May 2017, the FDA approved
1
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edaravone, a potent free radical scavenger. However, these drugs only slow the advance of
the disease meaning that the search for a cure continues. It is thus essential to unveil the
mechanisms implicated in ALS pathogenesis to find early and specific diagnostic methods
and develop effective therapies that allow not only to decrease disease progression but
also to deal with the secondary consequences such as respiratory failure. Therefore, phar-
maceutical companies and medical centers have been sponsoring clinical trials to test
several drugs that are thought to be protective against ALS pathology. Furthermore, re-
cent studies have suggested that bioactive compounds such as polyphenols are protective
for several neurodegenerative disorders [16, 49, 72].
One powerful approach for studying the mechanisms underlying neurodegenerative
diseases has been the use of animal models. Indeed, invertebrates such as Drosophila
melanogaster have been proven extremely valuable as a model organism for human neu-
rodegenerative disorders such as ALS [36]. Hence, genetic studies using Drosophila have
provided novel insights into disease development. These models are also excellent in vivo
systems for the testing of bioactive molecules [38, 42]. Thus, the principal objective of this
study was to test the therapeutic benefits of a small bioactive molecule (Compound C) on
the progressive neurodegeneration induced by ALS-related FUS alleles, using Drosophila
as a model organism. Compound C was previously tested for its protective properties in
a yeast model overexpressing FUS, one of the genetic hallmarks of the disease.
1.2 Amyotrophic Lateral Sclerosis
ALS is marked by the degeneration of motor neurons which are a group of efferent neu-
rons, within the spinal cord and the brain, that makes synapses with muscle fibers to
control muscle activity. There are two main types of motor neurons namely upper mo-
tor neurons (UMN) and lower motor neurons (LMN). Upper motor neurons originate
in the brain (motor cortex) and project downward to connect with lower motor neurons.
The latter localize both in the brainstem and the spinal cord and their axons connect di-
rectly with muscles at the Neuromuscular Junction (NMJ). Thus, they connect the Central
Nervous System (CNS) with the target muscle to be innervated (Figure 1.1) [22, 66].
ALS was first described in 1869 by Jean-Martin Charcot. He suggested that “the name
reflects both the degeneration of corticospinal motor neurons, whose descending axons
in the lateral spinal cord appear scarred (“lateral sclerosis”), and the demise of spinal
motor neurons, with secondary denervation and wasting of muscle (“amyotrophy”)” [66].
However, the disease only became well-known when the baseball player Lou Gehrig an-
nounced his ALS diagnosis in 1939. Therefore, Amyotrophic Lateral Sclerosis is also
known as Charcot disease, Lou Gehrig’s disease or motor neuron disease (MND). There
are four other known MNDs: Primary Lateral Sclerosis (PLS), Progressive Muscular Atro-
phy (PMA), Progressive Bulbar Palsy (PBP) and Pseudobulbar Palsy [76].
There are two types of ALS disease. The most common form is sporadic ALS (sALS),
2
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accounting for 90-95% of the cases, which has no genetically inherited component. Ap-
proximately 5-10% of the cases are inherited from a family member and are classified
as family-type ALS (fALS). The disease is considered familial when there are two or
more family members affected. Usually, the onset is earlier in fALS, although the clinical
presentation of inherited ALS and sporadic ALS is similar [1, 66, 69].
Figure 1.1: The components of the nervous system impacted in ALS pathogenesis. De-
scending corticospinal motor neurons (upper motor neurons) are the first ones affected
by ALS, they project from the motor cortex to synapses in the brainstem and spinal cord.
Bulbar or spinal motor neurons (lower motor neurons) projects from the brainstem or
spinal cord to skeletal muscles [Adapted from [66]].
ALS is an orphan disease affecting, in general, 1-2 individuals per 100.000 each year
in most countries. Since ALS has a rapid lethality, its prevalence is much lower. Although
rare, ALS is the most common motor neuron disease affecting people of all races and
ethnicities with a higher prevalence among Caucasians [16, 34, 65].
1.2.1 Clinical phenotypes
Usually, the first symptoms begin between 50 and 65 years old with the median age-
onset of 64 years. According to statistics, only 5% of the cases correspond to an age-onset
younger than 30 years old, while the beginning over 80 years old presents a high incidence
(10.2/100.000 in men and 6.1/100.000 in women) which can set aging as a risk factor for
the disease [6, 76].
ALS has a wide phenotypic variability and often shows clinical overlap with other
neurodegenerative disorders being frontotemporal dementia (FTD) the most common.
3
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Thus, identification of specific phenotypes is essential to develop strategies to measure
disease progression and improve survival [66].
Different phenotypes can be distinguished based on the body region first affected at
disease onset. When ALS symptoms begin in the arms or legs, it is termed "limb onset"ALS.
In this case, individuals may have difficulties with simple tasks such as writing or walking.
On the other hand, ALS that begins by affecting the muscles of speech, chewing and
swallowing is referred as "bulbar1 onset"ALS. Limb onset is found in around 80% of the
cases but most patients will develop symptoms in both bulbar region and limbs as the
disease progresses (Figure 1.2) [34, 53].
ALS affects both upper and lower motor neurons. However, ALS beginning usually
presents symptoms associated with only upper or lower motor neuron involvement lead-
ing to a wrong diagnosis. Thus, patients can be diagnosed with primary lateral sclerosis
(PLS), presenting only UMN level phenotype, or progressive muscular atrophy, which
has only LMN participation (PMA). As the disease progresses, ALS exhibit a detectable
involvement of both UMN and LMN, and diagnosis reclassification must be accomplished
to discard previous diagnostics of PLS or PMA (Table 1.1) [34, 57, 66].
Figure 1.2: ALS clinical phenotypes. (A) Wasting of upper limb leading to an inability
to lift arms against gravity. (B) Recessions above and bellow the scapular spine showing
wasting of supraspinatus and infraspinatus muscles and partial loss of deltoid muscle.
(C) Disproportionate wasting of the thenar muscles and also the first dorsal interossei
comparatively with hypothenar muscles in hand – the typical "split-hand."(D) Substantial
wasting of the tongue muscles in bulbar onset ALS [Adapted from [34]].
1Bulbar region is an area of the brain composed of the cerebellum, medulla and pons [57].
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Table 1.1: Clinical presentations in amyotrophic lateral sclerosis. Symptoms are di-
vided by affected motor neuron. Both UMN and LMN have to be affected for ALS diagno-
sis [34, 53].
Upper motor neuron sign in bulbar onset
Spasticity;
Spastic dysarthria.
Lower motor neuron sign in bulbar onset
Tongue wasting;
Weakness;
Fasciculations;
Flaccid dysarthria;
Later dysphagia.
Upper motor neuron sign in limb onset
Spasticity;
Weakness;
Brisk deep tendon reflexes.
Lower motor neuron sign in limb onset
Fasciculations;
Muscle atrophy;
Weakness.
Some factors influence prognosis. Low survival is associated with bulbar-onset disease,
older ages at the time of disease development and early respiratory muscle dysfunction
while high survival is related with the limb-onset disease, younger age at the beginning
of the disorder and delayed diagnostic [34, 73].
In final disease stages, patients need help with daily life activities and if they develop
dyspnea at rest, the death becomes imminent. Usually, patients die from respiratory
failure or other pulmonary complications. Sometimes they are kept alive by tracheostomy
assisted ventilation developing a profound state motor paralysis known as “totally-locked-
in-state” (TLS) in which all voluntary movements are lost [28, 48, 73].
1.2.2 Genetics
“There is considerable evidence of a genetic contribution to all ALS”[2].
Sporadic ALS refers to the cases that have no familial inheritance. However, techno-
logical advances in DNA sequencing revealed the presence of mutations in ALS genes
in the sporadic population, confirming the genetic contribution also in this form of the
disease. Thus, the cause of sALS probably involves a combination of genetic and environ-
mental factors. Familial ALS occurs as a result of mutations in a specific genetic locus
and the inheritance is primarily autosomal dominant following a Mendelian pattern [5,
11, 66, 76].
In the last years, several studies contributed to generate a list of genes whose muta-
tions are associated with both types of ALS. Given that one of the principal objectives of
this work was to test the effect of a small molecule in a Drosophila model overexpressing
FUS, the following topic will discuss the role of this gene [66].
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1.2.2.1 Fused in Sarcoma (FUS)
Fused in Sarcoma is a RNA-binding protein, ubiquitously expressed in all cells, that plays
an important role in the regulation of RNA transcription, splicing and transport. The N-
terminal of FUS protein has properties for transcriptional activation and the C-terminal
contains domains involved in RNA-protein interactions [58, 62].
The majority of FUS mutations (accounting for 4% of fALS and less than 1% of sALS)
are missense mutations in the C terminus of the protein, where the nuclear localization
signal (NLS) is positioned (Figure 1.3). The most common mutations in human ALS pa-
tients are ’R521H’ and ’R521C’. FUS has nuclear and cytoplasmic expression and shuttles
between the cytoplasm and the nucleus. FUS mutations lead to a gain-of-toxicity mech-
anism that involves the redistribution of the protein from the nucleus to the cytoplasm
[60]. Thus, postmortem analysis of brain and spinal cord tissues from ALS patients carry-
ing FUS mutations demonstrated compromised FUS nuclear localization and abnormal
cytoplasmic FUS inclusions in neurons and glia. Furthermore, it has been proposed that
the overexpression of wild type FUS in vulnerable neurons may be one of the causes of
the disease [36, 45, 56, 72].
Figure 1.3: Schematic diagrams showing functional domains in FUS proteins and FUS
mutations identified in ALS. The human FUS gene is located on chromosome 16p11.2.
The full length human FUS protein contains 526 amino acids that can be further divided
into distinct functional domains, such as the “prion-like” or low complexity (LC) domain
that contains the Q/G/S/Y-rich region (amino acids 1-165) and the G-rich region (amino
acids 165-267), the Arginine-rich motif (RRM, amino acids 285-371), two Arg-Gly-Gly
(RGG)-repeat regions (amino acids 371-422 and 453-501), interrupted by a Cys2-Cys2
zinc-finger motif (ZNF)(amino acids 422-453), and a non-conventional nuclear localiza-
tion signal (NLS)(amino acids 510-526). Other structural and functional domains in FUS
include the prion-like domains and the HDAC1-interacting domains. R521C mutation is
higlighted by the red asterisk [Adapted from [62]].
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1.2.3 Pathogenic mechanisms
There are a large number of gene mutations associated with this disease. Thus, several
pathogenic mechanisms by which motor neurons degenerate have been proposed and it
seems likely that the combination of these mechanisms, instead of a single mechanism,
contributes to the neurodegeneration. The identification of toxic mechanisms is essential
for understanding disease progression and for the development of effective therapies. The
following topics discuss some principal mechanisms [8].
1.2.3.1 Free radical-mediated oxidative stress
In the last years, the interest in reactive oxygen species (ROS) have been increasing. They
are natural bioproducts of the normal metabolism of oxygen and can be generated in the
human body through several endogenous systems, exposure to various physicochemical
conditions or pathophysiological states. However, an imbalance between ROS production
and cell’s antioxidant defenses causes ROS accumulation and consequently oxidative
damage. In other words, disturbances in the cell’s ability to detoxify reactive species lead
to the accumulation of free radicals that can damage cell components including lipids,
proteins and DNA, causing mutagenesis. Moreover, due to the accumulation of free
radical damage in cells, organisms become aged and more susceptible to several diseases
including ALS [19, 49, 76].
Increased oxidative damage and accumulation of free radicals were found in cere-
brospinal fluid (CSF) and urine samples of ALS patients [76].
1.2.3.2 ER stress and unfolded protein response
Endoplasmic reticulum (ER) is the cellular organelle responsible for protein synthesis,
posttranslational processing, folding of newly synthesized proteins and delivering the
biologically active proteins to their proper target sites. Accumulation of unfolded and
misfolded proteins in the lumen of ER (excessive influx) or perturbations in the typical en-
vironment necessary for protein folding leads to ER stress. In this regard, a physiological
response known as Unfold Protein Response (UPR) is triggered off in the cell to relieve ER
stress by transcriptionally regulating ER chaperones and other proteins, attenuating the
overall translation rate and increasing the degradation of misfolded proteins. However,
if the ER functions are severely affected and it is not possible to restore the cell integrity,
the cell undergoes apoptosis [31, 59, 66].
Previous studies found deposits of granular or amorphous material in the ER lumen of
sporadic ALS patients, which can be associated to an accumulation of misfolded proteins,
suggesting a relation between ER stress and motor neuron degeneration [31].
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1.2.3.3 Protein aggregates
Protein aggregation represents one of the principal pathological hallmarks of ALS. Under
normal conditions, cells can handle mutant proteins sufficiently well preventing their
toxic gain of function and also their sequestration into inclusions. However, under patho-
physiological circumstances, the ubiquitin proteasome system (UPS), that is activated to
maintain protein quality control, could become overloaded. This leads to the engulfment
of cells, which become defective in the disposal of altered macromolecules [7, 46, 50].
Recent studies have identified molecular constituents of ALS-linked cellular aggre-
gates, including FUS. Despite strong evidence that protein aggregation is a hallmark of
ALS, many questions remain about the role, formation and mechanism-of-action of these
protein aggregates [7].
1.2.3.4 Neuroinflammation
The occurrence of a neuroinflammatory reaction is usually found in neurodegenerative
disorders (including ALS) and consists of activated glial cells, mainly microglia and astro-
cytes, and T cells. Microglia are the resident macrophages 2 in the nervous system; they
constantly monitor the extracellular environment, interacts with astrocytes and neurons
and are the first line of defense against infection or injury to the nervous system. Astro-
cytes are ectodermal cells that have many complex functions in the nervous system such
as regulating extracellular neurotransmitter concentrations, supporting surrounding neu-
rons and maintain extracellular ion balance. Finally, T cells are a type of lymphocyte
which infiltrates the CNS modulating the neuroinflammatory reaction differently in each
stage of disease progression [52].
Several studies have shown that microglial activation is usually triggered by the infil-
tration of helper T cells3 and cytotoxic T cells4. The presence of T cells is rare in early ALS
stages, but readily infiltrate the spinal cord as the disease progresses. At the end stage
of disease cytotoxic T cells predominate; thus, some hypothesis suggests that it explains
why neuroprotective action ultimately fails (Figure 1.4) [52].
In the last years the interest in the contribution of microglia, astrocytes and T cells
to motor neurons degeneration has been increasing and has given rise to clinical trials of
drugs targeting neuroinflammatory reactions in ALS patients [52, 66].
2Macrophages are specialized cells involved in the detection, phagocytosis and destruction of bacteria
and other harmful organisms [21].
3Helper T cells are a type of T cell that helps stimulate B cells (type of white blood cell of the lymphocyte
subtype) to make antibodies and activates macrophages to kill ingested microorganisms [29].
4Cytotoxic T cells are a type of T cell that kills virally infected cells and tumours [68].
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Figure 1.4: Interaction of inflammatory T cells with microglia and astrocytes in ALS
pathology. (A) At asymptomatic stages of the disease, almost no T cells are found in the
spinal cord. (B) At early stages of the disease, inflammatory T cells infiltrate the spinal
cord from the blood. These T cells are mainly helper T cells which interact with sur-
rounding microglia and astrocytes. Here, their neuroprotective action (thick arrow, +)
overcome their neurotoxic effect (dashed arrow, -). (C) At later disease stages, cytotoxic
T cells predominate in the spinal cord. These cells could trigger the production of a neu-
rotoxic environment (thick arrows, -) instead of a neuroprotective environment (dashed
arrows, +) surrounding motor neurons leading to their degeneration and consequently
death. Th = helper T cell. Tc = cytotoxic T cell [Adapted from[52]].
1.2.3.5 Mitochondrial dysfunction
Mitochondria are rod-shaped organelles considered the “powerhouse” of cells since they
convert energy into ATP which is essential for cells metabolism. They also have roles
in vital processes including the production of cellular respiration, calcium homeostasis
and control of apoptosis. Previous studies reported functional defects and morphological
changes of mitochondria in skeletal muscle of ALS patients suggesting that mitochondrial
abnormalities could be related to ALS. Moreover, a proposed mechanism suggests that
mutant SOD1 is imported into mitochondria damaging this organelle and activating cell
death [14, 41, 76].
1.2.3.6 Impaired axonal structure and disrupted transport
Motor neurons typically have extremely long axons (on the order of meter long) that can
be vulnerable to damage. Axons conduct electrical impulses known as action potentials
but also transports organelles, RNA, proteins and lipids to and from a neuron’s cell body.
Axonal transport is crucial for the survival of motor neurons and can be anterograde or
retrograde. It is called anterograde transport when it moves away from the cell body,
toward the synaptic structures at the neuromuscular junction, mediated by kinesins. On
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the other hand, moving toward the cell body is called retrograde transport and it is
mediated by cytoplasmic dynein [17, 76].
Dysfunction of both axonal transport, anterograde and retrograde, and axonal cy-
toskeletal disorganization, especially of neurofilaments, have been identified as causes
of motor neuron degeneration. Defects in axonal transport can lead to an accumulation
of neurofilaments, mitochondria and autophagosomes in motor neurons. In this regard,
some experiments have shown that in the presence of ALS-linked SOD1 mutants, both
anterograde and retrograde transport are slowed, months before degeneration. In addi-
tion, several studies have shown that mutation in dynactin, an activator of cytoplasmic
dynein, has been associated with a reduction in retrograde transport leading to motor
neurons degeneration [17, 66].
1.2.3.7 Glutamate-induced excitotoxicity
During glutamatergic neurotransmission, glutamate released from the presynaptic neu-
ron activates ionotropic glutamate receptors5 in the postsynaptic neuron. The activation
of these glutamate receptors leads to the influx of Na+ and Ca2+ into the cell causing
depolarization and the generation of an action potential. Afterwards, glutamate is re-
moved from the synaptic cleft by excitatory amino acid transporters (EAATS). However,
an increased release of glutamate or a failure to rapidly remove synaptic glutamate in-
duces excitotoxity6. Nevertheless, it remains unclear if glutamate-induced excitotoxicity
is a primary defect responsible for motor neuron degeneration or it is the result of ALS
(Figure 1.5) [71].
5The ionotropic glutamate receptors are ligand-gated cation channels [71].
6Excitotoxicity describe the neuronal degenerative changes caused by over-stimulation of the glutamate
receptors [63, 71].
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.
Figure 1.5: Glutamatergic neurotransmission and excitotoxicity. (A) Under the normal
process, glutamate is released from the presynaptic neuron into the synaptic cleft activat-
ing the NMDA and AMPA ionotropic receptors in the postsynaptic neuron. This leads to
the influx of Na+ and Ca+ ions into the cell causing depolarization and generation of an
action potential. (B) Classical excitotoxity is induced by an increase of extracellular gluta-
mate concentration. This can be caused by an increased release of glutamate or failure in
reuptake of glutamate into the astrocytes by EAAT2/GLT-1 transporter. Thus, glutamate
receptors are excessively stimulated giving rise to an excessive increase of the intracellular
concentration of Na+ and Ca+ that can trigger motor neuron death. [Adapted from[71]].
Glutamate excitotoxicity has been associated with ALS due to the detection of high
glutamate concentrations in the cerebrospinal fluid (CSF) of several patients with sporadic
ALS. Moreover, the main argument for the role of excitotoxity in ALS is that riluzole, a
clinical drug that slows the progression of the disease, has anti-excitotoxic properties [15,
71].
1.2.4 Treatment
Currently, there is no available treatment to stop or reverse the progressive degenera-
tion of motor neurons in ALS. However, two clinical drugs can slow the progression
of symptoms and prevent complications. The first drug approved by the FDA for the
treatment of ALS was riluzole, a glutamate antagonist that blocks voltage-gated sodium
channels leading to a decrease in the pre-synaptic release of glutamate. In May 2017, the
FDA approved edaravone, an intravenous drug that counteracts the excessive oxidative
stress in ALS by removing the free radicals in the nervous system. Indeed, these drugs
only prolong the survival and delay the use of surrogate approaches such as mechanical
ventilation. Hence, more than two decades after the acceptance of riluzole, the search for
new therapeutic strategies is essential [20, 46, 47, 51].
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1.3 Bioactive small molecules
Many studies have been supporting the possibility of changing the progression or the
development of neurodegenerative diseases through diet. Indeed, several findings have
been suggesting that bioactive molecules such as polyphenols7, the most abundant in
our diet, have protective effects in neurodegenerative disorders [23]. They are thought
to be effective in the prevention or reduction of the impact of reactive oxygen species
associated with oxidative stress and neurodegeneration because of their strong capability
to induce intracellular signaling pathways related to gene expression and cell survival
[32]. Hence, actual studies are trying to test their neuroprotective properties and also
understand which of the hundreds of natural polyphenols available in our diet provide
better effects [39, 49, 64].
Jimenez-Del-Rio et al. demonstrated that pure polyphenols such as gallic acid, ferulic
acid, caffeic acid, coumaric acid, propyl gallate, epicatechin, epigallocatechin, and epigal-
locatechin gallate protect, rescue and, most importantly, restore the impaired movement
activity induced by paraquat8 in Drosophila melanogaster [32]. Similarly, Maccioni et al.
revealed that standardized phytotherapic extracts, from medicinal plants widely used
in Ayurvedic medicine, restored anomalous locomotion (i.e. impaired climbing perfor-
mance with unexpected hyperactivity) and electrophysiological responses in a Drosophila
model of ALS [39].
However, it remains unclear what concentrations are necessary to these small molecules
reach the brain and what biologically active forms are need to exert beneficial effects.
Therefore, more research is necessary to identify the molecular pathways and intracellu-
lar targets responsible for the protective effects of polyphenols [3].
1.3.1 Compound C
Edible berries are considered one of nature’s treasure chests not only because they are an
enjoyable fruit that provides energy, nutrients and dietary fiber, but also because they con-
tain a large number of polyphenols with health-promoting properties. However, berries
contain complex polyphenols mixtures making difficult to associate any interesting phar-
macological activity to a single small molecule. For this reason, under the European
BacHBerry project, more than twenty selected berry extracts, based on their metabolomic
profile, were systematically analyzed to identify small molecules that have protective
properties against neurodegenerative disorders. These extracts were tested on different
Saccharomyces cerevisiae strains overexpressing proteins related to Alzheimer’s, Parkin-
son’s, Huntington’s or ALS disease that confer toxicity in yeast. After the identification of
blackberry (Rubus genevieri) extract as having bioactivity against ALS, it was fractionated
7“Polyphenols are a group of chemical substances present in plants, fruits, and vegetables, characterized
by the presence of one or more than one phenol unit per molecule with several hydroxyl groups on aromatic
rings” [32].
8Paraquat is a superoxide generator that induces oxidative stress [37].
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and the obtained fractions were re-tested in the yeast model of ALS overexpressing FUS
protein. All fractions were analyzed for its content by liquid chromatography coupled to
mass spectrometry and some isolated small molecules from the bioactive fractions were
re-tested. This screening revealed that Compound C displayed significant bioactivity in
the yeast ALS model. So, Compound C was identified as a powerful protectant against
pathological mechanisms associated with ALS disease in a yeast model overexpressing
FUS (Figure 1.6) [30].
Figure 1.6: Compound C protects the yeast model of ALS from FUS toxicity. FUS over-
expression impairs cellular growth (red) compared with the control (green) and treatment
with Compound C rescues cellular growth (blue) [Unpublished results].
1.4 Drosophila melanogaster as a model system to study
FUS-induced ALS disease
As an animal model, Drosophila has several advantages that make it extremely useful and
important for biomedical research. Indeed, the relative simplicity, short lifespan, easy and
cheap maintenance, approachable physiology and huge availability of powerful genetic
tools make it a very attractive model to the study of several topics such as development,
behavior and the basis of human disease [49, 67].
In particular, Drosophila models containing ALS-associated transgenes have been im-
portant tools for understanding disease pathogenesis. Previous studies showed that the
expression of wild type or mutant human FUS alleles such as FUS[R521C] in the eye,
motor neurons or the nervous system of the fly leads to eye degeneration, defects in loco-
motion and increase in mortality [36]. Thus, the Drosophila model of ALS overexpressing
13
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human FUS alleles recapitulates the majority of ALS characteristics including progres-
sive motor deficits, motor neuron degeneration and early lethality. However, the ALS-like
phenotypes in these animal models are highly dependent on transgene expression levels
and severity of phenotypes correlate with level of protein overexpression [77].
Interestingly, the homolog of human FUS gene in Drosophila corresponds to cabeza
(caz) gene on X chromosome, that shares 53% amino acid identity to its mammalian
counterpart. The Drosophila Caz protein has 399 amino acids and is expressed in neurons,
glia and muscle cells [62].
1.5 Objectives and proposed approaches
This project had two main goals:
• Characterize the neuronal and kinematic decay of a Drosophila model of ALS;
• Test the effect of candidate small molecule (Compound C) in the motor decay of the
Drosophila model of ALS.
Since FUS is one of the principal candidates in ALS development, our first step was to
mimic the human disease by overexpressing human wild type FUS and human FUS with
targeted mutagenesis (R521C). Once we profiled the mutant FUS induced degeneration
at the kinematic level, we tested the protective effect of a small molecule (Compound
C) previously tested for their capability to improve cellular growth of the yeast model
overexpressing FUS.
The use of adult Drosophila as a model to test the efficacy of small molecules has
multiple advantages. First, it allows challenging neurons in an in vivo, whole body context.
Second, due to the fly’s relatively short life span, it is possible to follow in a feasible time
period the degeneration of motor activity. Finally, we can quantify with high detail a
large set of locomotor features of animals undergoing degeneration, allowing detecting
any relevant suppressions in the motor decay process.
To achieve the proposed goals, we performed survival, climbing and egg laying assays
and we also analyzed the neurodegeneration in the fly eyes. Furthermore, a detailed anal-
ysis of the locomotor pattern of the flies modeling ALS disease using the FlyWalker was
done. This approach was used to correlate cellular demise with specific kinematic conse-
quences to the animals and most importantly, to quantitatively profile neurodegeneration
that was critical to detect putative suppression of the neurodegenerative phenotype. Fi-
nally, we indirectly quantified the number of motor neurons establishing synapses with
leg muscles.
Since the ultimate goal was to ameliorate the locomotor symptoms associated with
ALS pathology, we fed the flies with Compound C in these experiments and tested its
effect on the motor decay induced by the expression of FUS alleles.
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Material and methods
2.1 Preparation of the fly food
The two concentrations of Compound C tested (7.5mM and 10mM) were obtained through
successive dilutions, starting from a stock solution of Compound C dissolved in DMSO
(500mM). In the cases that the flies were treated with RU486, 20µL of this compound
was added to the 10 mM or 7.5 mM solutions (Figure 2.1).
Finally, 150µL of the selected solution were impregnated in the vials containing fly
food overnight. With this method, the compound was not mixed in all the food, it just
impregnated a few centimeters. However, given that the flies were transferred to new
vials twice a week, they just ate the food at the surface.
Figure 2.1: Protocol followed to obtain the different concentrations of Compound C
tested.
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2.2 Fly eye imaging
Eye phenotypes of one-day-old female flies were evaluated using Leica S6E and the images
were acquired on Zeiss Stereo LUMAR stereoscope. The flies were placed at -80ºC for five
minutes, before the imaging. For each genotype, 10 to 30 flies were evaluated. Embryos,
larvae and pupae were exposed to DMSO or Compound C throughout their development
and maintained at 25ºC in incubators without light.
2.3 Life span assay
Flies were crossed in the absence of DMSO, Compound C or RU486 on a standard food
medium. Day 1 adult females were transferred on to new experimental vials containing
fly food mixed either with DMSO or Compound C dissolved in DMSO, with (+) or without
(-) RU486 (1 mM), at a density of 25 flies per vial for each genotype (n=3). Deaths were
scored every two days and flies were transferred to fresh food two times a week. All the
flies were maintained at 25ºC in incubators under a 12 h light/dark cycle.
2.4 Climbing assay
Motor function was assessed by a negative geotaxis response assay, commonly called
climbing assay. Briefly, groups of 10 males of the same age of each genotype were placed
into 18-cm-long vials, at room temperature for environmental acclimatization, and 10
min later they were tapped to the bottom of the vial. The climbing time was recorded
when 50% of the population (five flies) crossed the 8-cm or the 15-cm finish line. At least
50 flies were tested in five independent groups of males per condition. Results are the
average climbing time of these separate trials. The males were exposed to vehicle (DMSO)
or Compound C from day one adult-stage and maintained at 25ºC in incubators under a
12 h light/dark cycle.
2.5 Egg laying assay
Reproductive outputs of the flies expressing FUS alleles were assessed by quantifying the
number of laid eggs and emerged larvae. Briefly, five males and 15 virgin females, for each
condition, were used for mating. After seven days of mating, males were discarded. At the
selected time-points (seven, 14 and 21 days), ten female flies of each group were randomly
selected and placed into apple juice agar plates during 24 hours and then the number of
laid eggs was quantified using Leica S6E. Five days later, the number of emerged larvae
was also registered (Figure 2.2). Adult flies, eggs and larvae were maintained at 25ºC in
incubators under a 12 h light/dark cycle. Females were exposed to vehicle (DMSO) or
Compound C, both mixed with RU486, from day one adult stage. This experiment was
performed two times (n=2).
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Figure 2.2: Schematic showing the procedure of the egg laying assay.
2.6 Quantification of motor neuron projection in the leg NMJ
In order to keep leg motor neuron axonal morphology intact for imaging, the legs were
dissected and fixated carefully. Five flies per condition were selected and placed into
empty tubes. To remove the hydrophobicity of the cuticle, the flies were washed in
ethanol (not more than one minute). Afterwards, they were rinsed three times in 0.3%
Triton in 1x phosphate buffered saline (PBS) (for one, five and 30 minutes in each wash) to
increase penetration of the fixative inside the leg and then, the flies were dissected in this
medium. Basically, the head and the abdomen of the flies were removed using forceps and
then the coxa-thorax junction was gently but firmly pushed using the tip of fine forceps
until the leg detached. Subsequently, the fixation was done in 4% paraformaldehyde
(PFA) in PBS overnight at 4ºC (approximately 20 hours total). Later, the legs were washed
three times in PBT, for 20 minutes each wash at room temperature. Finally, the legs were
mounted into glass slides using 70% glycerol medium. The imaging was done with a
Zeiss LSM710 confocal microscope using a 40x water immersion objective.
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2.7 FlyWalker basis
It is challenging to quantify walking behavior in Drosophila due to its small size and the
lack of available tools. In order to overcome this limitation, Mendes et al. described an
approach that can be used to examine the walking patterns of Drosophila melanogaster.
The authors developed an optical touch sensor that is based in frustrated Total Internal
Reflection (fTIR) method coupled with high-speed video imaging which detects the fly’s
body and leg contacts on the floor during locomotion [43].
Total Internal Reflection occurs when light travels from a medium with a high refrac-
tive index, in this case optical glass, to one with a lower refractive index such as air. If
the angle of incidence is higher than the critical angle (as compared to the normal of
the surface), defined by Snell’s Law, the light is internally reflected rather than refracted.
However, when a denser material such as the tarsus of an insect leg touches the surface
of the glass, the locally ‘frustrated’ total internal reflection will scatter the light and that
can be recorded by a high-speed video camera (Figure 2.3) [40, 43, 44].
Each movie is acquired at 250 frames per second and it can be analyzed frame-by-
frame. In each frame, the fTIR effect allows to visualize the fly legs that are in contact
with the glass and also the fly body due to the background light (Figure 2.3). Afterwards,
the tracking of each tarsal contact and the fly body is done with the FlyWalker program
(Figure 2.4). This custom-made software evaluates the fTIR signals in terms of pixel
intensity in each movie and outputs several graphs and user-defined kinematic param-
eters that can be used to describe fly walking behavior with high temporal and spatial
resolution. The parameters include step, spatial and gait parameters [43].
Figure 2.3: Schematic of the fTIR optical effect. (A) Detailed description of the fTIR
apparatus. Light that comes from LED light sources located at the edges of an optical
glass propagates within the glass by internal reflection. Tarsal contacts lead to light
scattering which can be recorded by a high-speed video camera. (B) Single frame of a
fTIR movie. The fTIR effect can be seen for three legs in stance phase (yellow arrows).
The orange dashed ellipse corresponds to the body delimitation; the center of the body is
indicated by an orange cross [Adapted from[43]].
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Figure 2.4: Image generated by the FlyWalker software. The fly’s footprints and body
center are tracked throughout the video. It is possible to identify the present footprints
(yellow arrows), the past footprints (red arrows) and the fly body and trajectory (white
arrow). Step length, which is defined as the distance between two consecutive footprints,
can also be visualized (green arrows) [Adapted from[43]].
2.7.1 Step parameters
Drosophila has six legs and, in a step cycle, each leg goes through a period of stance phase,
in which the leg is touching the ground, or a swing phase meaning that it is up in the air.
Previous findings have shown that, in several insect species, when the speed increases,
stance phase duration becomes shorter and swing phase duration remains predominantly
constant; at the higher speeds, the duration of both stance and swing phases becomes
equal [25, 74].
One of the parameters that it is possible to extract from FlyWalker analysis are the
step parameters that are related to individual leg movement. These parameters include
the duration of stance and swing phases, step frequency (number of steps per second),
step period (time taken to complete one leg cycle), step length (distance between two
successive footprints of the same leg), average speed and swing speed (Figure 2.5) [43].
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Figure 2.5: Step pattern of a general fly walking at 40 mm/s (average) obtained with
the FlyWalker software. The swing and the stance phases are represented by the black
and white regions, respectively. The step period, swing duration and stance duration are
indicated by the arrows [Adapted from [43]].
2.7.2 Spatial parameters
The spatial parameters are related to the perception of the surface. They analyze the first
and last moments that the leg contacts with the glass surface and how much straight are
the stance traces generated between those moments. The onset of these traces, which
corresponds to the position where the leg first touches the glass, is termed the Anterior
Extreme Position (AEP) while the end of stance traces, before the tarsi enter swing phase,
corresponds to the Posterior Extreme Position (PEP). For each stance trace, a smoothed
version of the trace is generated and the average of the difference between these two lines
allows to calculate the stance linearity index parameter. Thus, faster flies have straighter
stance traces (lower stance linearity indexes) when compared with slower flies. Another
spatial parameter is the stance straightness index that corresponds to the ratio between
the displacement (AEP-PEP vector length) and the path length. Footprint clustering is
also a relevant spatial parameter and it is related to the clustering of the AEP’s and PEP’s.
This parameter corresponds to the standard deviation from the average position for all
AEP’s or PEP’s calculated for each leg. For instance, if the footprint clustering value of
the foreleg AEP is small, it means that the AEP coordinates were similar for all the foreleg
steps in the video (Figure 2.6) [43].
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Figure 2.6: Schematic diagram of general spatial parameters obtained with the Fly-
Walker software. (A) Representation of the stance strances for each leg of a general fly.
AEP and PEP positions are also identified. (B) Method to calculate the stance linearity
index. It can be obtained by computing the average difference between an actual stance
trace and a smoothed trace. (C) The stance straightness index indicates how much wig-
gly is the body center relative to each footprint and corresponds to the ratio between
the displacement and the path length. (D) Method to quantify footprint clustering. An
average ±STD xy point is generated (blue cross) for each set of AEP/PEP footprints (red
circles). The footprint clustering value is calculated as the vector sum of the two STD
values (orange arrow) [Adapted from[43]].
2.7.3 Gait parameters
Gait parameters analyze coordination between legs. Insect gaits can be either tripod or
tetrapod (Figure 2.7), depending on the speed and body load. Flies usually walk using
tripod gait which is characterized by three legs in stance phase and three legs in swing
phase at any one time. Each group of three legs is constituted, on one side, by the fore
and hind legs and, on the contralateral side, by the middle leg. In contrast, a tetrapod
gait is characterized by two legs in swing phase and the remaining four legs in stance
phase. The two legs in swing phase are localized on contralateral sides and are offset by
one segment. It is also observed several non-canonical stance combinations that do not
fit in these idealized gaits. In addition, at slow speeds flies occasionally walk with only
one leg in swing phase which characterizes the so-called ‘wave gait’ in which individual
legs swing in a wave-like pattern from front to back [43].
For each video, a step pattern can be generated (Figure 2.5) and the instantaneous
speed and gait characteristics are simultaneously plotted with high temporal resolution
(Figure 2.7). The instantaneous speed plot has a wave-like appearance in which the
minimum speeds correspond to the transition between phases, when the stance switches
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to a different group of legs. For each frame in a video, it is possible to classify if the
fly is in a tripod, tetrapod or non-canonical stance (sometimes wave gait is also used).
These results are plotted in a gait map that graphically shows the gaits used over time
(yellow for tripod, blue for tetrapod, and grey for non-canonical). To quantify the gait
maps, the tripod, tetrapod and non-canonical indexes are calculated. These gait indexes
correspond to the percentage of frames in a video that displays leg combinations defined
by the tripod, tetrapod and non-canonical gait, respectively [43].
Figure 2.7: Schematic diagram of some gait parameters obtained with the FlyWalker
software. (A) Representation of the different gaits and leg combinations used by the flies
during the walk. Black circles and ‘1’ corresponds to stance phase and white circles and
‘0’ means swing phase. (B) Speed and gait graphs obtained with the FlyWalker software
for a general fly walking at 40mm/s on average. The color code corresponds to the gaits
used by the fly overtime in all the movie. It is possible to visualize that this female fly
used mostly the tripod gait which corresponds to higher values of body velocity [Adapted
from [43]].
2.8 FlyWalker procedure
2.8.1 Fly preparation
The flies used to perform the FlyWalker analysis were raised at the same conditions as
outlined in the survival assay. Before the acquisition, each group of flies was anesthetized
with ice and placed 30 minutes into empty vials to clean their legs.
2.8.2 Data acquisition
The image acquisition was done with a Photron (1024 x 336) or a Point Grey camera
(2048 x 1088), both at a frame rate of 250 frames/s. It was necessary to clean up the
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optical glass where the flies walk with optic cleaning fluid before the acquisitions. Each
fly was inserted into the fly chamber using a mouth aspirator and the acquisition of the
data started immediately after the insertion; thus, flies did not have time to adapt to the
surrounding environment. Moreover, the duration of the acquisition did not last longer
than one minute. For each time point, approximately seven to ten flies were evaluated.
2.8.3 Movie cropping
The temporal cropping of the movies acquired with the Point Grey and the Photron cam-
eras was done with the StreamPix 6.5.0.0 and the Photron FASTCAM Viewer 3.6.9.1
(PFV3) software, respectively. The videos were temporally cropped by selecting the first
and the last frames, giving rise to small sequences of .png files. The chosen sequences
contained a series of five to six step cycles for each leg, where the fly walks straight and
from left to right. Then, the sequences acquired with the Point Grey were load in Im-
age J software to be spatially cropped in order to have a smaller image containing the
sequence of interest. The movies acquired with the Photron camera were cropped tempo-
rally and spatially using the same software, PFV3. In total, approximately 120 movies
were cropped.
2.8.4 Fly tracking using the FlyWalker software
The custom-made FlyWalker software, written in MATLAB® R2016b, was used to per-
form the fly tracking process. The first step was to load the sequence to be analyzed
through this software. Then, the length of the fly was measured, with the option "ruler"available
in the interface, and introduced in the software settings. Moreover, the threshold values
for the legs and body were defined in the settings to optimize the auto-tracking pro-
cess. After the auto-tracking, the detection of the legs and the center of the body were
confirmed. If there were detected any defects, it was done hand correction. If not, the
evaluation of the movie proceeded. The evaluation process resulted in a set of graphs
(including the stance traces, the step pattern, the gait map,...) and also a Microsoft Excel
file with all the kinematic parameters that describe the walking patterns of each fly.
2.8.5 Data analysis
The Excel file includes a summary line containing all the parameters and their values. To
compare different conditions, these lines were all grouped in another Excel file. Then,
for each motor parameter, a scatter graph containing the raw data of the different groups
was generated using the Excel tools. From here, it was possible to observe and select the
relevant variables for further analysis. The parameters were considered relevant when it
was possible to distinguish the groups of interest in the scatter plots.
Based on this first approach, the next step was to calculate the residual values using
a script written in R. Given that most of the kinematic parameters vary with speed, the
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R script determined the best fit regression model for the control condition and then it
computed the residual values for each experimental condition in relation to this regres-
sion model. After, the data was expressed as the difference to the residual-normalized
line in PCA, heat map and box plots. To perform statistical tests, it was necessary to
verify if the data was normally distributed and homoscedastic (i.e. equal variance for all
predictors). The normality assumption was confirmed using the Shapiro-Wilk test and
the homoscedasticity assumption was confirmed using the Levene’s Test. Afterwards, if
the data was considered normally distributed and homoscedastic, the test used was one-
way-ANOVA. The null hypothesis of this test is that the means of all groups considered
were the same. If the null hypothesis was rejected (p-value < 0.05), it was performed
the Tukey’s post hoc test between each group and the control. Otherwise, if data was
not normal and homoscedastic, non-parametric tests were performed. In these cases, for
comparisons of more than three groups, it was used Kruskal-Wallis analysis of variance.
If the null hypothesis, that the median of all groups was the same, was rejected (p-value
< 0.05), the Dunn’s post hoc test was performed to see the significant differences between
each group and the control. The graphic representations such as the heat maps and the
PCA were made with scripts written in Python 3.4 software. The box plots were done
with GraphPad Prism software version 7.
2.8.5.1 Residual values - Detailed explanation
To calculate the residual values, a regression analysis was performed in order to find the
best fit (linear or non-linear) for each parameter of the control condition. Afterwards,
the residuals were obtained by computing the distance of each value (including control
values) to the regression model (Figure 2.8). There was one residual for each data point.
They were positive if they were above the regression model and negative if they were
below the regression line. If the point passed through the regression line, the residual at
that point was zero.
Figure 2.8: Method to obtain residual values. The best fit model is indicated by the red
arrow. A residual is the vertical distance between a data point and the regression line
(blue).
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2.8.5.2 Principal Component Analysis (PCA)
Principal Component Analysis is a technique commonly used for dimensionality reduc-
tion. Briefly, it projects a complex dataset onto a lower-dimensional space that still con-
tains most of the information in the large set. Since PCA “ignores” class labels, it can be
described as an “unsupervised” algorithm. Thus, the objective of this method is to find
directions (called principal components) that maximize the variance of the data. The first
principal component explains the most extensive variance in the original data set. The
second principal component is determined in the same way, with the condition that it is
perpendicular to the first principal component and that it accounts for the next highest
variance. This continues until a total of n principal components have been computed,
equal to the original number of variables. For visualization, usually the first one, two or
three principal components are used to plot the data in an attempt to reveal any groupings
[33, 70].
2.9 Overall statistical considerations
Most of statistical analyses were done using GraphPad Prism software version 7. For
the survival assays, it was performed a Log-rank (Mantel–Cox) test. For climbing and
egg laying assays, it was performed a two-way ANOVA followed by a Tukey post-test.
In the FlyWalker analysis, statistical tests were performed as outlined above. It was
used "ns"for non-significant data. Statistic significant were considered when ∗pvalue ≤
0.05,∗ ∗ pvalue ≤ 0.01,∗ ∗ ∗pvalue ≤ 0.001.
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Results and Discussion
3.1 Ectopic expression of human FUS alleles leads to
neurodegeneration in Drosophila eyes
In order to observe the effects of the expression of human ALS-related FUS alleles in
the fly eyes, transgenic flies overexpressing wild type (WT) or mutant (R521C) human
FUS in the eyes were generated using the GAL4/UAS system. Comparing to the control
(UAS-GFP), the expression of FUS alleles using GMR-gal4, an eye driver, caused severe
neurodegeneration in Drosophila eyes characterized by disorganized ommatidia and loss
of pigmentation and mechanosensory bristles. Moreover, the FUS alleles reflected the ex-
pected strength, with the phenotype of mutant human FUS more aggressive than the wild
type form. Nonetheless, the misexpression of FUS[WT] also induced neurodegeneration
(Figure 3.1).
These results demonstrate that the expression of human ALS-related FUS alleles
causes neurodegenerative phenotypes which is consistent with the gain-of-toxicity mech-
anism that has been proposed for ALS disease. Furthermore, they confirm that the
FUS[R521C] allele causes stronger degeneration that the wild type version [36].
In addition, it was analyzed the expression of other FUS alleles such as FUS[R518K]
and FUS[R521H] in the fly eyes. However, no differences were observed regarding the
control which was probably due to problems in transgene generation (data not shown).
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Figure 3.1: Imaging of day 1 adult fly eye expressing FUS alelles (B,C) under the control
of GMR-gal4 driver (A).
3.1.1 Compound C does not ameliorate the neurodegenerative phenotype in
the fly eyes
To try to suppress the neurodegenerative phenotype, flies with the same genotype as
above were fed with Compound C during development. Given that Compound C was
dissolved in DMSO, another batch of flies was supplied only with DMSO in order to use
it as a control for further comparison. Thus, two concentrations of Compound C were
tested: 7.5mM and 10mM (Figure 3.2).
After the treatment with Compound C, no visible modifications were found in the fly
eyes. In addition, the eye phenotypes of the flies fed with DMSO were similar to the ones
found for the standard condition (Figure 3.1).
Taken together, the results suggest that, in these concentrations, DMSO is not toxic
for the flies and the exposure of the fly to a medium supplemented with Compound C
does not ameliorate the neurodegenerative phenotypes caused by the expression of FUS
alleles in the eyes.
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Figure 3.2: Eye neurodegenerative phenotypes after the treatment with Compound C.
These flies were supplemented with (A) 7.5mM and (B) 10 mM of DMSO (first row) and
Compound C (second row) during development.
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3.2 Conditional expression of human FUS alleles in
Drosophila neurons increases mortality
To mimic the human disease in Drosophila, FUS alleles were overexpressed in the neurons
of the fly using the conditional expression system ElaV-GeneSwitch (ElaV-GS). Briefly,
following treatment with RU486, the Gene Switch protein was transcriptionally activated
and bound to UAS inducing the expression of the respective FUS protein specifically in
the nervous system [36].
Then, the effects of the neuronal FUS expression on the life span of the flies were
determined by monitoring their survival rate from day one adult stage on. Given that one
of the objectives of this project was to test the protective effect of Compound C, it was
considered two groups of females flies: one fed with standard food mixed with the vehicle
and another one supplied with Compound C (10mM). In each group, three genotypes
were considered: ElaV-GS;UAS-GFP (control), ElaV-GS;UAS-FUS[WT] and ElaV-GS;UAS-
FUS[R521C], each one treated with or without RU486 (1mM). For each condition, 75 flies
were analyzed.
In the group fed with the vehicle, there was very low mortality in the flies expressing
the driver alone treated with (+) or without (-) RU486, since >90% flies were viable after
30 days of DMSO exposure in both cases. However, the induction of FUS[WT] and FUS
[R521C] in adult neurons caused a decline in the survival rate when compared with the
driver alone, even in RU486 untreated flies (-), which was not expected. Furthermore,
the induction of FUS[R521C] drastically shortened the life span when compared with
FUS[WT]. These findings revealed a mutation-dependent decline in the life span of the
FUS[R521C] expressing animals. However, flies expressing FUS[WT] also exhibited a
decline in life span, but the degree of severity was less than mutant FUS animals (Figure
3.3).
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Figure 3.3: Lifespan of female flies expressing FUS alleles under the control of ElaV-
GS. The survival curves show the percentage of flies alive as a function of age. In both
flies maintained with (+) or without (-) RU486, the FUS alleles are expressed and the neu-
ronal expression of FUS[R521C] strongly decreases the lifespan, whereas the expression
of FUS[WT] has a weaker effect on the reduction of life span. Control flies showed normal
life span with many flies living after the end of the experiment. In the FUS alleles, the max-
imum survival (in days) is indicated for each condition (the mean values indicate the num-
ber of days it took for half of the flies to die): FUS[WT] - RU486 49 (mean=33), FUS[WT]
+ RU486 43 (mean=28), FUS[R521C] - RU486 37 (mean =26), FUS[R521C] + RU486 38
(mean =28). The controls are significantly different from all the other conditions (***)
(P<0.001) but they are not significantly different from each other (log-rank, Mantel–Cox
test). Statistical significances for FUS alleles are indicated bellow the graph. Statistic
significant were considered when ∗pvalue ≤ 0.05,∗ ∗ pvalue ≤ 0.01,∗ ∗ ∗pvalue ≤ 0.001.
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3.2.1 Exposure to DMSO (corresponding to the 2% used in the 10mM of
compound C) is not toxic for the flies
To confirm that DMSO was not causing any toxicity in the flies, a survival assay was
performed with flies treated only with standard food mixed with RU486. Given that the
obtained curves are not significantly different from the ones achieved for DMSO, it seems
that DMSO is not toxic for the flies at 2%, its final concentration (Figure 3.4).
Figure 3.4: Life span of female flies expressing FUS alleles under the control of ElaV-
GS - DMSO toxicity. The survival curves show the percentage of flies alive as a function
of age. The control condition corresponds to the standard feeding. In the three genotypes,
the survival of the control condition is not significantly different from the survival of flies
fed with DMSO (log-rank, Mantel–Cox test).
3.2.2 The treatment with Compound C extends the life span of FUS[WT]
flies
Flies were fed with Compound C during the adult-stage and their lifespan was examined.
Comparing to animals fed DMSO, Compound C extended the lifespan of flies expressing
FUS[WT] under treatment with RU486 (Figure 3.5). Indeed, 50% of FUS[WT] flies fed
with DMSO were dead after 28 days with all of the flies dead in 43 days. On the other
hand, in flies expressing FUS[WT] fed with Compound C, approximately 50% of flies were
gone after 36 days and there was one fly that survived beyond the end of the study (50
days). These results propose that Compound C ameliorates the decline in the survival rate
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caused by the expression of FUS[WT] in the neurons of the fly using RU486. In addition,
Compound C did not extend the life span of the flies expressing FUS[521C] possibly
because this phenotype is too aggressive or because it kills by a distinct mechanism
insensitive to Compound C.
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Figure 3.5: Lifespan of female flies expressing FUS alleles under treatment with Com-
pound C - comparison with vehicle. The survival curves show the percentage of flies
alive as a function of age. Each row corresponds to a different genotype (under treat-
ment with or without RU486): (A) ElaV-GSxUAS-GFP, (B) ElaV-GSxUAS-FUS[WT] and
(C) ElaV-GSxUAS-FUS[R521C]. The graphs suggest that Compound C only increases the
life span of the flies expressing FUS[WT] in the presence of RU486. In this case, the
curves are significantly different from each other (***) (P<0.001) (log-rank, Mantel–Cox
test).
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3.3 FlyWalker analysis
Given that in the survival assay Compound C extended the life span of flies express-
ing FUS[WT], the FlyWalker analysis was done with two genotypes: the control (ElaV-
GS;UAS-GFP) and ElaV-GS;UAS-FUS[WT] under the treatment with RU486. Further-
more, the movies were recorded in time points where motor impairment was visible but
not severe, which increased the possibilities to detect any suppression of the degenerative
phenotype (Figure 3.6).
Figure 3.6: Selected time points to do the movies using the FlyWalker system.
3.3.1 A global statistical analysis suggests that the locomotor defect
induced by the expression of FUS[WT] is evident at 14 days and the
treatment with Compound C partially rescues this motor phenotype
Given that there is a considerable number of motor parameters that characterize the
motor behavior of each fly, several Principal Component Analysis with one (Figure 3.7),
two or three (Figure 3.8) principal components were performed in order to reduce the
complexity of the data and increase interpretability. The principal components were
calculated using residual normalized data, expressed as the difference to the control (7
days old ElaV-GS;UAS-GFP flies treated with DMSO).
The PCA allowed comparing the different groups visually. The graphs obtained show
that all the flies expressing the driver alone are similar to each other and also to the
seven days old FUS[WT] flies supplied with DMSO, in terms of the motor phenotype.
Furthermore, 14 and 21 days old FUS[WT] flies treated with DMSO and 21 days old
FUS[WT] flies supplied with Compound C are also proximate to each other. However,
they are apart from the flies expressing driver alone and from the younger FUS[WT] flies.
Therefore, these results suggest that the neurogenerative phenotype of FUS[WT] flies is
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evident at 14 days old. In addition, the FUS[WT] flies treated with Compound C are
closer to the 14 days old than the 21 days old flies with the same genotype and supplied
with DMSO, which is visible in the spatial parameters (Figure 3.7 B) and in statistical
tests comparing the three conditions (data not shown). Thus, although the flies treated
with Compound C do not reach the motor phenotype of flies expressing driver alone, it
seems that they approach the 14 days old flies, which could mean either a reverse on
disease development or a delay on disease progression.
Figure 3.7: Global PCA: step, spatial and gait motor parameters projection onto one
principal component. The figure represents the projection of (A) step (B) spatial and
(C) gait parameters onto one principal component that accounts for the largest possible
variance in the data set. "PC"means "Principal Component". In each condition, the
centroid correspond to the average position for all points.
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Figure 3.8: PCA: motor parameters projection onto principal components. The figures
represent the projection of all the motor parameters onto two and three principal compo-
nents respectively represented in the first and the second column. The rows are linked to
(A) the distribution of all the flies expressing driver alone, (B) the evolution of the motor
phenotype of flies expressing FUS[WT] over time, and (C) the comparison between the
treatment with Compound C and vehicle, at 21 days old.
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3.3.2 Deep statistical analysis
As referred above, this work had a two-fold objective. Thus, a deep statistical analysis
was done for each one of the goals. Again, the statistical differences were calculated
considering the residual values for each parameter.
3.3.2.1 The expression of FUS[WT] affects kinematic parameters of the fly over
time
After analyzing the raw data, some kinematic parameters were selected for statistical
analysis. Thus, the statistical differences between each condition and the control (seven
days old ElaV-GSxUAS-GFP flies treated with DMSO) were plotted in a heat map (Figure
3.9) and the variation of the data of each group was represented in box plots, among vari-
ous step (Figure 3.10), spatial (Figure 3.11) and gait parameters (Figure 3.12). Moreover,
the statistical differences between groups were represented in the box plots.
Consistent with the results obtained for PCA, the heat map and the box plots show that
the misexpression of FUS[WT] affects some locomotor parameters of the flies over time.
For instance, FUS[WT] expressing flies older than seven days old walk slower and take
fewer steps, in each step cycle, than flies expressing driver alone at the same ages (Figure
3.10). Furthermore, the stance traces of 14 and 21 days old FUS[WT] expressing flies are
visibly wigglier than the traces of younger flies with the same genotype and the traces
of the flies expressing driver alone. Indeed, the quantification of the spatial parameters
indicates that the Stance Linearity parameter of the FUS[WT] flies increases and their
Stance Straightness decreases over time (Figure 3.11). In addition, visual inspection of
the gait maps suggests that FUS[WT] flies older than seven days old walk more using
tetrapod gait rather than tripod, when compared to flies expressing driver alone at the
same ages. Indeed, the Tripod index of FUS[WT] expressing animals decreases over time
and the Tetrapod index becomes higher (Figure 3.12). As a matter of fact, it is well known
that as the animals decrease their speed they increasingly use tetrapod and non-canonical
combinations [43].
These findings underscore the hypothesis that animals modeling ALS disease be-
come more uncoordinated over time. In addition, it should be noted that seven days
old FUS[WT] flies are not statistically different to the control condition in most of the
kinematic parameters which confirms that the motor phenotype is evident, at least, at 14
days.
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Figure 3.9: Time dependent degeneration induced by FUS[WT] - statistically signifi-
cant results. Rows are related to the 13 kinematic parameters that were analyzed. These
are grouped in three major categories: step, spatial and gait parameters. The area framed
with the colored lines represents the genotypes: the blue frame indicates the columns that
belong to the flies expressing driver alone and the orange frame highlights the columns
for FUS[WT] expressing animals. Moreover, each column is linked to one of the time
points analyzed (seven, 14 and 21 days) for each genotype. Colored squares represent
statistically significant results. White squares represent no significant differences to the
control (seven days old ElaV-GSxUAS-GFP flies treated with DMSO). Warm colors are
significant results that had higher values than the control. Cold colors are the significant
results with lower values than the control. A one-way ANOVA followed by a Tukey post-
test was done for normal and homoscedastic data. Otherwise, a Kruskal-Wallis one-way
ANOVA with Dunn’s multiple comparison test was applied. Statistic significant were
considered when ∗pvalue ≤ 0.05,∗ ∗ pvalue ≤ 0.01,∗ ∗ ∗pvalue ≤ 0.001.
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Figure 3.10: Time dependent degeneration induced by FUS[WT] in step parameters.
The colors are linked to the genotypes: the blue color corresponds to the driver alone
and the orange represents the FUS[WT] expressing flies. The median as the middle line,
with the lower and upper edges of the boxes representing the 25% and 75% quartiles,
respectively; the whiskers represent the range of the full data set, excluding outliers.
Circles indicate outliers. Data was residual normalized and expressed as the difference to
the control. A one-way ANOVA followed by a Tukey post-test was done for normal and
homoscedastic data. Otherwise, a Kruskal-Wallis one-way ANOVA with Dunn’s multiple
comparison test was applied. Statistic significant were considered when ∗pvalue ≤ 0.05,∗∗
pvalue ≤ 0.01,∗ ∗ ∗pvalue ≤ 0.001.
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Figure 3.11: Time dependent degeneration induced by FUS[WT] in spatial parameters.
(A) Stance traces representation of neurodegeneration induced by FUS[WT], in which the
Stance Linearity, the AEP/PEP Footprint Clustering and the Stance Straightness can be
observed, over the six time points considered. The quantification of these four metrics
was made in (B). The colors are linked to the genotypes: the blue color corresponds to the
driver alone and the orange represents the FUS[WT] expressing flies. The median as the
middle line, with the lower and upper edges of the boxes representing the 25% and 75%
quartiles, respectively; the whiskers represent the range of the full data set, excluding
outliers. Circles indicate outliers. Data was residual normalized and expressed as the
difference to the control. A one-way ANOVA followed by a Tukey post-test was done
for normal and homoscedastic data. Otherwise, a Kruskal-Wallis one-way ANOVA with
Dunn’s multiple comparison test was applied. Statistic significant were considered when
∗pvalue ≤ 0.05,∗ ∗ pvalue ≤ 0.01,∗ ∗ ∗pvalue ≤ 0.001.
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Figure 3.12: Time dependent degeneration induced by FUS[WT] in gait parameters.
(A) Gait maps representation of neurodegeneration induced by FUS[WT], in which the
Non-canonical, Tripod and Tetrapod indexes can be observed, over the six time points
considered. The quantification of these three metrics was made in (B). The colors are
linked to the genotypes: the blue color corresponds to the driver alone and the orange
represents the FUS[WT] expressing flies. The median as the middle line, with the lower
and upper edges of the boxes representing the 25% and 75% quartiles, respectively; the
whiskers represent the range of the full data set, excluding outliers. Circles indicate
outliers. Data was residual normalized and expressed as the difference to the control. A
one-way ANOVA followed by a Tukey post-test was done for normal and homoscedastic
data. Otherwise, a Kruskal-Wallis one-way ANOVA with Dunn’s multiple comparison
test was applied. Statistic significant were considered when ∗pvalue ≤ 0.05,∗ ∗ pvalue ≤
0.01,∗ ∗ ∗pvalue ≤ 0.001.
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3.3.2.2 The treatment with Compound C improves the Swing Speed of FUS[WT]
expressing flies
Once profiled the kinematic and the statistical analysis of FUS-induced motor impair-
ment, the putative suppression of the neurodegenerative phenotype (through the treat-
ment with Compound C) was analyzed. Regarding this objective, the residual values were
expressed as the difference to the control ’21 days old ElaV-GSxUAS-GFP flies treated
with DMSO’. The statistical differences between each condition and the control were
plotted in the heat map (Figure 3.13). Moreover, the variation of the data of each group
was represented in box plots. They were grouped in three categories: step (Figure 3.14),
spatial (Figure 3.15) and gait (Figure 3.16) parameters.
The results propose that the treatment with Compound C improves the Swing Speed
of FUS[WT] expressing flies. Consequently, the Swing Duration becomes shorter (Figure
3.14). Furthermore, there are no significant changes in the stance traces of FUS[WT]
expressing animals treated with Compound C compared to the ones exposed to DMSO,
according to the Stance Linearity, AEP/PEP Footprint Clustering and Stance Straightness
parameters (Figure 3.15). Similarly, the gait parameters do not reveal differences between
these two conditions (Figure 3.16). Thus, although the treatment with Compound C does
not improve the most of impaired motor parameters through the FUS[WT] expression, it
improves the step parameter Swing Speed.
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Figure 3.13: Effect of Compound C on the neurodegeneration of the flies - statistically
significant results. Rows are related to the 13 kinematic parameters that were analyzed.
These are grouped in three major categories: step, spatial and gait parameters. The area
framed with the colored lines represents the genotypes: the dark blue frame indicates
the columns that belong to the flies expressing driver alone and the orange frame high-
lights the columns for FUS[WT] expressing animals. Moreover, each column is linked to
one type of treatment: Compound C or DMSO. Colored squares represent statistically
significant results. White squares represent no significant differences to the control (21
days old ElaV-GSxUAS-GFP flies treated with DMSO). Warm colors are significant re-
sults that had higher values than the control. Cold colors are the significant results with
lower values than the control. A one-way ANOVA followed by a Tukey post-test was done
for normal and homoscedastic data. Otherwise, a Kruskal-Wallis one-way ANOVA with
Dunn’s multiple comparison test was applied. Statistic significant were considered when
∗pvalue ≤ 0.05,∗ ∗ pvalue ≤ 0.01,∗ ∗ ∗pvalue ≤ 0.001.
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Figure 3.14: Effect of Compound C on the neurodegeneration of the flies in step pa-
rameters. The colors are linked to the genotypes: the dark blue color corresponds to
driver alone and the orange represents the FUS[WT] expressing flies. The median as the
middle line, with the lower and upper edges of the boxes representing the 25% and 75%
quartiles, respectively; the whiskers represent the range of the full data set, excluding
outliers. Circles indicate outliers. Data was residual normalized and expressed as the
difference to the control. A one-way ANOVA followed by a Tukey post-test was done
for normal and homoscedastic data. Otherwise, a Kruskal-Wallis one-way ANOVA with
Dunn’s multiple comparison test was applied. Statistic significant were considered when
∗pvalue ≤ 0.05,∗ ∗ pvalue ≤ 0.01,∗ ∗ ∗pvalue ≤ 0.001.
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Figure 3.15: Effect of Compound C on the neurodegeneration of the flies in spatial
parameters. (A) Stance traces representation of effect of Compound C, in which the
Stance Linearity, the AEP/PEP Footprint Clustering and the Stance Straightness can be
observed, over the four time points considered. The quantification of these four metrics
was made in (B). The colors are linked to the genotypes: the blue color corresponds to the
driver alone and the orange represents the FUS[WT] expressing flies. The median as the
middle line, with the lower and upper edges of the boxes representing the 25% and 75%
quartiles, respectively; the whiskers represent the range of the full data set, excluding
outliers. Circles indicate outliers. Data was residual normalized and expressed as the
difference to the control. A one-way ANOVA followed by a Tukey post-test was done
for normal and homoscedastic data. Otherwise, a Kruskal-Wallis one-way ANOVA with
Dunn’s multiple comparison test was applied. Statistic significant were considered when
∗pvalue ≤ 0.05,∗ ∗ pvalue ≤ 0.01,∗ ∗ ∗pvalue ≤ 0.001.
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Figure 3.16: Effect of Compound C on the neurodegeneration of the flies in gait param-
eters. (A) Gait maps representation of effect of Compound C, in which the Non-canonical,
Tripod and Tetrapod indexes can be observed, over the four time points considered. The
quantification of these three metrics was made in (B). The colors are linked to the geno-
types: the blue color corresponds to driver alone and the orange represents the FUS[WT]
expressing flies. The median as the middle line, with the lower and upper edges of the
boxes representing the 25% and 75% quartiles, respectively; the whiskers represent the
range of the full data set, excluding outliers. Circles indicate outliers. Data was residual
normalized and expressed as the difference to the control. A one-way ANOVA followed
by a Tukey post-test was done for normal and homoscedastic data. Otherwise, a Kruskal-
Wallis one-way ANOVA with Dunn’s multiple comparison test was applied. Statistic
significant were considered when ∗pvalue ≤ 0.05,∗ ∗ pvalue ≤ 0.01,∗ ∗ ∗pvalue ≤ 0.001.
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3.4 Expression of FUS alleles in the adult flies causes severe
motor dysfunction using the climbing assay
Given that the FlyWalker outputs a set of parameters for each fly and that it was observed
a considerable heterogeneity within each FUS genotype during the life span assay (there
were healthier flies on the top of the vials), it was done a negative geotaxis assay in order
to have a response of a group of animals. Again, two groups were considered: DMSO and
Compound C. Moreover, there were considered the same genotypes as in the survival
assay, all of them supplemented with RU486 during the adult stage.
To assay the climbing ability of flies fed with DMSO, 10 male flies of each condition
were tapped to the bottom of the vial and allowed to climb up the walls. The climbing
time was recorded when five flies crossed a 15-cm finish line [54].
The results demonstrate that the climbing ability of the flies expressing the driver
alone was not affected. However, the expression of FUS alleles in the neurons of the fly
caused severe motor dysfunction over time, compared to controls. Moreover, for each
time point, flies expressing FUS[R521C] took more time to reach the finish line than the
FUS[WT] which suggests that the mutant flies have a stronger impairment of the motor
abilities (Figure 3.17). In addition, after 12 days, the flies expressing FUS alleles were not
able to climb; they became weak and fell a lot. Collectively, these findings confirm that
the expression of FUS alleles in the neurons leads to time dependent neurodegeneration
that progressively affects the climbing ability of the flies.
3.4.1 The treatment with Compound C during seven days does not rescue
the climbing ability of flies expressing FUS alleles
After, a comparison between seven days old flies of both groups was performed, consider-
ing two finish lines: 8 cm and 15 cm. Given that the difference between the flies treated
with DMSO and Compound C is not significant, the results suggest that the treatment
with Compound C (during seven days) does not rescue the climbing ability of the flies
expressing FUS alleles (Figure 3.18).
After 12 days, it was not possible to perform the climbing assay either with flies
exposed to DMSO or Compound C since they were not able to climb, even decreasing the
high to 8 cm.
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MOTOR DYSFUNCTION USING THE CLIMBING ASSAY
Figure 3.17: Climbing ability of flies expressing FUS alleles under the control of ElaV-
GS. The y-axis represents the time (in seconds), it took for five males to climb 15 cm (mean
± SEM). Statistical significance within groups is represented on the graph and statistical
significance between groups is represented in the tables bellow. These differences were
calculated by doing two-way ANOVA with Tukey post-test. Statistic significant were
considered when ∗pvalue ≤ 0.05,∗ ∗ pvalue ≤ 0.01,∗ ∗ ∗pvalue ≤ 0.001.
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Figure 3.18: Effect of Compound C on the climbing ability of flies expressing FUS
alleles. The y-axis represents the time (in seconds), it took for five males to climb (A)
8 cm and (B) 15 cm (mean ± SEM). In each genotype, flies treated with or without
Compound C are not significantly different. Statistical significance was calculated by
doing two-way ANOVA with Tukey post-test. Statistic significant were considered when
∗pvalue ≤ 0.05,∗ ∗ pvalue ≤ 0.01,∗ ∗ ∗pvalue ≤ 0.001.
3.5 The induction of FUS alleles lead to a decrease in laid eggs
and emerged larvae
It is well established that egg production from females or viable offspring from males
is a marker of toxicity in Drosophila [37]. Besides, the egg laying ability is a neuronal
controlled behavior [75]. Thus, after observing that female flies overexpressing FUS alle-
les (WT and R521C) had a larger abdomen than with the driver alone, it was performed
an egg laying assay in order to analyze their reproductive outputs and understand if the
larger abdomen was related to an impaired egg laying ability.
It was measured, in different time points, the number of laid eggs during 24 hours
and the sequential number of emerged larvae. Regarding the first objective of this work,
the characterization of the neuronal degeneration induced by FUS alleles, the flies were
exposed to DMSO from day one adult stage on. These flies were used as a control for
further comparison with the ones exposed to Compound C.
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AND EMERGED LARVAE
Female flies exposed to DMSO while overexpressing FUS alleles (under treatment
with RU486) exhibited a significant reduction in the number of laid eggs and emerged
larvae, compared to control. Moreover, flies expressing FUS[WT] laid, on average, more
eggs than the flies expressing mutant FUS. The number of emerged larvae was also higher
in FUS[WT] condition at seven days old (Figure 3.19).
Interestingly, these results reveal that the expression of FUS affects the egg laying
ability and the larvae emergence, with mutant FUS phenotypes stronger than the wild
type form.
Figure 3.19: Egg laying and larvae emergence of female flies expressing FUS alleles
under the control of ElaV-GS. The graphs represent (A) the number of laid eggs and
(B) the percentage of eggs that turns into larvae (fertilized eggs), per plate and genotype,
among various time points. Data are presented as means ± SEM and analyzed by two-
way ANOVA with Tukey post-test. Statistic significant were considered when ∗pvalue ≤
0.05,∗ ∗ pvalue ≤ 0.01,∗ ∗ ∗pvalue ≤ 0.001.
3.5.1 The treatment with Compound C does not rescue the egg laying
ability and larvae emergence in FUS expressing flies
After the treatment with Compound C during 14 days, the number of laid eggs and
emerged larvae was quantified. Then, a comparison between the two groups (DMSO and
Compound C) was done (Figure 3.20).
FUS expressing animals exposed to Compound C exhibited a significant decrease in
reproductive outputs, compared to control, as observed with DMSO. Indeed, the number
of eggs laid by females treated with Compound C was not affected by the treatment.
Similarly, Compound C does not rescue the larvae emergence.
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Figure 3.20: Effect of Compound C on the egg laying ability and larvae emergence of
flies expressing FUS alleles. The graphs represent (A) the number of laid eggs and (B)
the percentage of eggs that turns into larvae (fertilized eggs), per plate and genotype,
among various time points. Data are presented as means ± SEM and analyzed by two-
way ANOVA with Tukey post-test. Statistic significant were considered when ∗pvalue ≤
0.05,∗ ∗ pvalue ≤ 0.01,∗ ∗ ∗pvalue ≤ 0.001.
3.6 Flies expressing FUS alleles do not show changes in the
motor neuron projections in the leg NMJ
The Drosophila adult leg is organized into segments as the vertebrate limb. Each fly leg
has 14 muscles, each one comprising multiple muscle fibers. The cell bodies of the adult
leg are located in the T1 (prothoracic), T2 (mesothoracic), and T3 (metathoracic) ganglia
on each side of the ventral nerve cord (VNC)1. Each ganglia comprises approximately 50
motor neurons that target muscles in four segments of the ipsilateral leg - coxa, trochanter,
femur and tibia (Figure 3.21) [27].
1VNC is a structure analogous to the vertebrate spinal cord [27].
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MOTOR NEURON PROJECTIONS IN THE LEG NMJ
Figure 3.21: Schematic of the adult Drosophila leg motor system. It is possible to vi-
sualize the cell bodies of the adult leg motor neurons (green) which are localized in the
cortex (grey) of the thoracic ganglion of the VNC. Motor neurons arborize their dendrites
in the leg neuropil (blue) and project their axons into the leg innervating one of the 14 leg
muscles (red). It should be noted that only the T1 legs are schematized [Adapted from
[27]].
Since ALS targets motor neurons without short-term cell death, an indirect quan-
tification of the number of motor neurons establishing synapses with leg muscles was
performed. This was carried out by co-expressing Rab3:YFP, which marks presynaptic
regions in motor neurons using the LexA/LexAop system, a binary expression system
independent of the GAL4 system. YFP was visualized through the leg cuticle and imaged
by confocal microscopy. The flies were fed with DMSO during the adult stage to further
compare with Compound C effect.
It was expected a decrease in the Rab3:YFP presence in the legs of FUS expressing
flies. However, it was not detected possibly because there are a huge number of motor
neurons establishing synapses with leg muscles which makes difficult to perform any
quantification (Figure 3.22). Concerning that, the effect of Compound C was not tested.
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Figure 3.22: Visualization of neuro-muscular junctions (NMJs) in the adult leg.
Synapses established between motor neurons and muscles in the leg can be visualized
using Rab3:YFP (green). Legs are mounted in slides and visualized using confocal mi-
croscopy. Leg cuticles can be visualized by acquiring the autofluorescence in the red
channel (second column). An overlap of both can be visualized in the third column.
These legs belong to seven days old flies. Yellow arrows indicate the trochanter.
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Conclusions
4.1 Summary
Several Drosophila models of ALS have emerged in the last decade by mimicking human
alleles of the disease. In one of these examples, Lanson et al. showed that the overexpres-
sion of human FUS alleles in Drosophila leads to neurodegeneration in the eyes, reduced
longevity and locomotor defects [36]. In this work, we tried to replicate these results
and investigate other readouts related to FUS-induced degeneration. Moreover, we tested
whether Compound C delays the progression of the neurodegenerative phenotypes.
First, we reported the generation and characterization of transgenic flies expressing
wild type and a mutant form of human FUS (R521C). We showed that ectopic expression
of ALS-related FUS alleles in Drosophila eyes leads to neurodegenerative phenotypes
characterized by ommatidial degeneration, partial collapse and loss of eye pigmentation.
Moreover, we developed a conditional Drosophila model of FUS-related ALS using an
inducible neuronal driver (ElaV-GS). The overexpression of mutant human FUS in adult
fly neurons drastically increased mortality and led to behavioral abnormalities when
compared with FUS[WT] and driver alone. These findings are consistent with previous
reports, showing that the overexpression of mutant FUS in neurons can cause reduced
lifespan and climbing defects. Interestingly, FUS[WT] expressing flies also presented
reduced lifespan and climbing dysfunction. However, their phenotype was less severe
than that with mutant FUS, revealing that the expression of FUS[WT] in neurons is also
toxic and that neuronal tissues are particularly vulnerable to FUS levels.
Motor decay of freely walking fruit flies was quantified using a method developed
previously: the FlyWalker system. This methodology provides not only more information
but also higher sensitivity compared to classical motor assays. Here, we analyzed driver
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alone and FUS[WT] flies raised in the same conditions as in the survival assay, under treat-
ment with RU486. The results confirmed the FUS[WT]-induced neurodegeneration over
time. Indeed, the FUS[WT] expression affected kinematic parameters that characterize
the locomotor behavior of the flies. Furthermore, the statistical analysis showed clearly
that the motor phenotype is visible after 14 days of FUS[WT] expression.
Since the animals expressing FUS in all the neurons had a larger abdomen than with
the driver alone, an interesting phenotype was also investigated: the reproductive output.
In fact, FUS expressing flies showed a reduction in the number of laid eggs and emerged
larvae compared to control, with a higher decrease in mutant FUS animals, in general.
These effects on reproduction could be due to the fact that the egg laying behavior is
neuronal controlled [75].
Regarding the Compound C effect, it is undeniable that this small molecule signifi-
cantly extended the lifespan of FUS wild type expressing animals under treatment with
RU486. Moreover, in the FlyWalker analysis, the treatment with Compound C during
21 days increased the Swing Speed of FUS[WT] expressing flies, but the mechanisms
underlying the improvement of this kinematic parameter are unknown. Interestingly, the
motor phenotype of 21 days old flies treated with Compound C approached to that of 14
days old flies treated with DMSO, instead of 21 days old, which could mean a reverse or a
delay on disease progression. Furthermore, the remaining assays suggest that Compound
C does not ameliorate the degeneration of the eye and the impaired climbing and egg
laying ability, which could be related to the sensitivity of these assays.
Overall, our Drosophila model displayed several features strikingly similar to those
found in ALS patients. In fact, our results recapitulate specific features of FUS-induced
neurodegeneration that are hallmarks of ALS. Furthermore, this project created a set
of protocols that allowed, in a relatively short period of time, testing Compound C for
its efficacy to prevent or delay the progression of neurodegenerative phenotypes. The
aforementioned methodologies can be easily carried out and provide quantifiable metrics
regarding the progression of the neurodegenerative phenotype contributing to a result
regarding the effect of a candidate compound. Importantly, these experiments could
be easily performed on other ALS models (for example SOD1 or TDP-43) in order to
understand if the observed effects are exclusive to FUS-mediated toxicity. Besides, the
same approach can be expanded to additional neurodegenerative conditions such as
Huntington or Parkinson’s disease.
4.2 Limitations of this work and proposal of possible solutions
The experiments performed in this work revealed that the FUS[R521C] expressing flies
exhibit degenerative phenotypes more aggressive than the FUS wild type flies. However,
this assumption can be considered misleading since we do not know the amount of FUS
protein that these flies express. One possible solution is to do a western blot. That way
we can quantify the FUS expression levels in each genotype and if both of them have the
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same level, we can confirm the aggressiveness of FUS[R521C]. In fact, we tried to perform
a western blot. However, since there are many limitations in the quality of commercially
available antibodies, it was not possible to achieve this quantification.
At advanced stages of the survival assay, there were impaired FUS expressing flies
at the bottom of the vials and healthier flies at the top which sets the variability within
genotypes as a factor that can mislead the results. To overcome this limitation, we can
increase the number of replications of some assays, such as the egg laying assay and
the FlyWalker analysis which have a lower number of repetitions compared to other
experiments.
Furthermore, it was not possible to visualize a decrease in the Rab3:YFP presence
in the legs of seven days old FUS expressing animals, compared to driver alone. One
possible solution is to repeat this experiment at another time point, such as 21 days.
Other suggestion is to mark the presynaptic regions only with a limited number of motor
neurons with Rab3:YFP, which increases the sensitivity of this assay.
To test varying concentrations of Compound C is another improvement that should
be considered in order to understand if there is a concentration which effect is more
pronounced. Moreover, this bioactive molecule could be tested at more time points. For
instance, in the FlyWalker assay, it would be interesting to test the effect of Compound C
at 14 days old since its effect on the motor phenotype could be more detectable at earlier
stages of the disease. In addition, other assays can be considered to test the protective
effect of this small molecule. Finally, it would be pertinent to analyze the mutant human
FUS expressing flies with the FlyWalker system at different time points.
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Fly Basis
I.1 Drosophila melanogaster features
Drosophila melanogaster, known as the fruit fly, is found worldwide in rotting fruit where
adult flies lay its eggs. In the last years, fruit flies have been cultured in the laboratory,
in bottles or shell vials, by using a solid food. The life cycle of fly has different phases
including egg, larvae, pupa and adult (Figure I.1). Raised at 25ºC in rich culture medium
in the laboratory, these insects have a very short generation time, approximately 10 days,
and each female can lay several hundred eggs. Since the length of the life cycle is de-
pendent on temperature, researchers can increase the life span of flies by raising them at
18ºC [67].
Figure I.1: The life cycle of Drosophila melanogaster. The larvae hatches approximately
one day after the egg is fertilized and in the next four or five days the larvae progress
from the first instar through the second instar to third instar stages. During pupation,
most of the larval tissues are destroyed and replaced by adult tissues [Adapted from [4]].
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The sequencing of the entire genome of the fly was one of the most important break-
throughs for the scientific community, particularly for the Drosophila research community.
The annotated genome sequence of Drosophila melanogaster, which has four pairs of chro-
mosomes, 180 million bases and 13.600 genes, indicated that more than 90% of the
fly genes are similar to the human and mouse genes. However, the Drosophila genome
offers a much simpler than mammalian models. The fly chromosomes are designated
as 2, 3, 4 and X/Y. The Y chromosome contains only a few genes that are essential for
spermatogenesis.
One advantage of Drosophila is that, for each chromosome, there were created balancer
chromosomes. These are special modified chromosomes designed by multiple, nested
chromosomal inversions. The balancer chromosomes are genetic tools used to prevent
crossing over between homologous during meiosis. If, for some reason, the crossing over
involving balancer chromosomes occurs, it results in chromatids which lacks some genes
or have duplicated genes and consequently leads to a non-viable progeny.
Importantly, a balancer chromosome also contain dominant mutations that are visible
phenotypic markers and thus enabling researchers to follow the balancer and genetic
insertions through crosses. Moreover, balancer chromosomes allows the maintenance of
lethal mutations in heterozygous stable stocks. Balancers are usually termed based on
the chromosome that they serve to stabilize (F for first, which is the X chromossome; S for
second; and T for third), with an M which means “multiply inverted”. M is followed by
a number and sometimes a lowercase letter to distinguish balancers of the same chromo-
some. Additionally, the genetic symbol for the principal markers carried by that balancer
is listed after the name. Some markers usually used in several studies are represented
below (Figure I.2)[26, 67].
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Figure I.2: Examples of Drosophila phenotypic markers. These markers aids on tracing
the inheritance of alleles. Wild-type (WT) refers to a Drosophila stock in which flies are
similar to those found in natural populations [Adapted from[12]].
I.2 Expression systems in Drosophila
I.2.0.1 GAL4/UAS
In the last 30 years, there has been a huge expansion in the genetic toolbox of model
organisms, particularly in the fruit fly. One example of tool development was the creation
of the GAL4/UAS system for targeted gene expression in Drosophila which constitutes
one of the most powerful tools for studying gene function [3, 10].
This system is based on the properties of the GAL4 transcription factor, derived
from the yeast Saccharomyces cerevisiae, which activates transcription of its target genes
by binding to upstream activation sequence (UAS). The UAS is a specific enhancer to
the GAL4 protein. The two components, GAL4 and UAS, are carried in different lines
allowing for several combinatorial possibilities. When flies of these two lines undergo
crossing, the GAL4 protein binds to the UAS activating the gene at the tissue that the
promoter is specific for (Figure I.3) [9, 13].
One of the advantages of this system is that the expression of toxic genes will only be
enabled when bound to the GAL4 transcription factor; thus, flies can carry the inactivated
form of a toxic gene and survive normally. Moreover, this system allows the study of the
effects of numerous genes through their over-expression or misexpression at several sites
in the body using the large collection of tissue-specific promoters available [13].
I.2.0.2 GeneSwitch/UAS
Gene Switch (GS) system is an inducible system that allows temporal and tissue-specific
control of gene expression in Drosophila. GS uses a modified GAL4 protein fused to a
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progesterone steroid receptor enabling the regulation of its GAL4 activity by the presence
or absence of the synthetic progesterone analogue mifespristone (RU486). In the presence
of RU486, the GAL4 is activated leading to increased gene expression. Conversely, in the
absence of RU486, GAL4 activity is maintained at a minimum (Figure I.3) [55, 61].
.
Figure I.3: Gal4/UAS and GeneSwitch/UAS systems. (A) The GAL4/UAS system enables
spatial control of gene expression. (B) The GS system allows temporal control of gene
expression due to a modified GAL4 protein that is active only when RU486 binds to the
fused progesterone steroid receptor [Adapted from[61]].
I.2.0.3 LexA/LexAop
A different binary system is based on the LexA transcription factor, derived from Es-
cherichia coli, that regulates expression of transgenes fused to a LexA operator-promoter
(LexAop) [35]. Basically, the GAL4 system is the default expression system for most stud-
ies owing to the abundance of characterized lines. The LexA/LexAop system is frequently
used in combination with GAL4 since it allows Drosophila researchers to simultaneously
perform two manipulations of gene expression [18, 35].
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